Company Research Report: SV Health Investors
Company Overview
- Name: SV Health Investors
- Mission: Transform healthcare one investment at a time, supporting diverse entrepreneurs to create and build breakthrough companies and treatments.
- When Was the Company Founded and By Whom: No information is available.
- Key People in the Company:
- Kate Bingham, Managing Partner
- Nikola Trbovic, Managing Partner
- Michael Balmuth, Managing Partner
- Paul LaViolette, Managing Partner & COO
- Where is the Company Headquartered:
- Boston, USA: 28 State Street, Financial District, Downtown Boston, Massachusetts 02109.
- London, UK: 71 Kingsway, London, WC2B 6ST.
- Number of Employees: Over 50 investment professionals and operating partners.
- Revenue of the Company: No information is available.
- What is the Company Known For: Specialist in healthcare investment with a track record of 30 years in the US and UK, focusing on biotechnology, healthcare growth equity, and medtech.
Products and Services
Investment Strategies
- Therapeutics:
- Focus on innovative breakthroughs to change therapeutic paradigms.
- Investments in novel science targeting unmet medical needs and creating transformational new medicines.
- Healthcare Growth:
- Provides growth capital for industry leaders transforming healthcare.
- Investment in companies innovating care delivery, digital health technologies, and medical products.
- Medtech:
- Invest in novel therapeutic and monitoring technologies.
- Emphasis on expanding patient access via telehealth and cost-efficient healthcare delivery models.
Funds
- Current Funds Managed:
- Therapeutics Funds: Biotech and dementia-focused investments.
- Growth Fund: Accelerates growth-stage healthcare companies.
- Medtech Convergence Fund: Early-stage medical device and monitoring technologies.
Recent Developments
- LoQus23 Therapeutics appointed Cyrus Mozayeni as Chair of the Board of Directors following a £35 million Series A fundraise to advance its MSH3 inhibitors for Huntington’s Disease.
- AdvanCell expanded collaboration with Lilly to develop targeted alpha therapeutic cancer treatments, leveraging proprietary Pb-212 technology.
- Australian radiopharma AdvanCell secured $112M in scale capital for manufacturing capacity in the U.S., focusing on α-emitters, including a prostate cancer clinical program.
Strategic Approach
- Investment Focus: Invests across biotech, healthcare growth, and medtech, with a focus on diversity and success of under-represented groups.
- Historical Commitments: Over $3.7 billion in historical commitments with 75 successful IPOs and M&As.
- Geographic Presence: Investments globally with teams based in Boston and London.
- Partnerships: Strategic collaborations with large companies like Lilly to leverage combined expertise and capabilities.
Achievements
- Long-standing track record as one of the oldest healthcare investment managers.
- Successful exit through IPOs and acquisitions solidifying its position in the healthcare investment community.
- Recognized as leaders in supporting and creating value in the life sciences and healthcare sectors.
Contact Information
- Boston Office: +1 617 367 8100
- London Office: +44 20 7421 7070
- General Inquiries: info@svhealthinvestors.com
- Press Contact: Hannah Maunder, Investor Relations: +44 7425 645407 / hmaunder@svhealthinvestors.com
SV Health Investors continues to pioneer investment in groundbreaking healthcare solutions by embracing diverse and talented innovators across the globe, solidifying its renowned status in the healthcare investment domain.
